Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTM1201AT
- Development stage
- Unknown
- Lead developer
- Brigham and Women's Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LTM1201AT is an investigational drug being studied as a potential treatment for obstructive sleep apnea (OSA). It is administered orally in capsule form before bedtime. The drug is part of a group of related compounds (including LTM1201AZ, LTM1201AD, and LTM1201AG) evaluated for their ability to improve upper airway muscle function during sleep and reduce the severity of OSA. The precise mechanism of action, molecular structure, and pharmacological class have not been disclosed in publicly available sources. The primary developer and sponsor for clinical research involving LTM1201AT is Brigham and Women's Hospital[2][3][9].
Beyond the preview
Go deeper on LTM1201AT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTM1201AT.